{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071399","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.721930+00:00","generated_at":"2026-05-21T09:39:02.760923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025","bullets":["Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.","March 2025 restructuring cut 34% workforce; cash runway extended beyond 2029.","Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen updated.","Initial NKX019 data across autoimmune indications expected H2 2025; both ISTs open.","Robert Ortmann, M.D. appointed VP Clinical Development, joining May 15, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071399","json":"https://secwatch.observer/filing/0000950170-25-071399.json","markdown":"https://secwatch.observer/filing/0000950170-25-071399.md","text":"https://secwatch.observer/filing/0000950170-25-071399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/0000950170-25-071399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/nktx-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:39:02.760923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}